Sonnet BioTherapeutics (SONN) Competitors

Unity Biotechnology (NASDAQ:UBX) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Is UBX or SONN more profitable?

Unity Biotechnology's return on equity of -119.70% beat Sonnet BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-119.70%	-45.86%
Sonnet BioTherapeutics	N/A	-408.93%	-174.13%

Does the media prefer UBX or SONN?

In the previous week, Unity Biotechnology had 9 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 11 mentions for Unity Biotechnology and 2 mentions for Sonnet BioTherapeutics. Unity Biotechnology's average media sentiment score of 0.59 beat Sonnet BioTherapeutics' score of 0.43 indicating that Unity Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Unity Biotechnology	Positive
Sonnet BioTherapeutics	Neutral

Do analysts prefer UBX or SONN?

Unity Biotechnology currently has a consensus price target of $5.33, indicating a potential upside of 445.89%. Sonnet BioTherapeutics has a consensus price target of $20.00, indicating a potential upside of 1,359.85%. Given Sonnet BioTherapeutics' higher probable upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than Unity Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sonnet BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, UBX or SONN?

Sonnet BioTherapeutics has higher revenue and earnings than Unity Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology	$240K	68.67	-$39.86M	-$1.62	-0.60
Sonnet BioTherapeutics	$1M	4.20	-$7.44M	N/A	N/A

Does the MarketBeat Community believe in UBX or SONN?

Unity Biotechnology received 160 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 84.62% of users gave Sonnet BioTherapeutics an outperform vote while only 67.41% of users gave Unity Biotechnology an outperform vote.

Company	Underperform	Outperform
Unity Biotechnology	Outperform Votes 182 67.41%	Underperform Votes 88 32.59%
Sonnet BioTherapeutics	Outperform Votes 22 84.62%	Underperform Votes 4 15.38%

Do institutionals and insiders hold more shares of UBX or SONN?

29.5% of Unity Biotechnology shares are held by institutional investors. Comparatively, 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. 5.8% of Unity Biotechnology shares are held by company insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more risk and volatility, UBX or SONN?

Unity Biotechnology has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Summary

Unity Biotechnology beats Sonnet BioTherapeutics on 10 of the 14 factors compared between the two stocks.